Skip to search formSkip to main contentSkip to account menu

Copaxone

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
40 mg/mL dose of glatiramer acetate injection three times a week will permit a simpler regimen for patients with relapsing forms… 
2013
2013
The invention relates to an acetic acid copaxone microsphere and a preparation method thereof. The preparation method is simple… 
2012
2012
Experience of 10-year administration of glatimer acetate (copaxone) in 74 patients with active remitting multiple sclerosis is… 
2012
2012
Authors have followed up 230 patients with multiple sclerosis treated with disease modifying drugs (DMD) using the data of the… 
2011
2011
El objetivo de este trabajo fue interrelacionar las alteraciones conductuales, neuroquimicas e inmunologicas inducidas por estres… 
2006
2006
In last decades, practical neurologists are able to use DMT in multiple sclerosis (MS) in every day practice. This paper presents… 
2006
2006
Multiple sclerosis (MS) is a multifactorial and polygenic disorder of the central nervous system, its development being under… 
2006
2006
A comparative analysis of efficacy and tolerability of such immunomodulating compounds as rebif 22-mcg and copaxone used in the… 
2005
2005
Tipe 1 T-helper cells are of importance in development of multiple sclerosis (MS). Copaxone (TEVA, Israel) is one of the… 
2002
2002
Results of the 2-year open postregistration study of Copaxone (glatiramer acetate), conducted in 3 Moscow leading medical centres…